{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:10:56Z","timestamp":1778764256810,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106689","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:32:13Z","timestamp":1755253933000},"page":"106689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical and cognitive outcomes in Ocrelizumab-treated MS patients: Insights into the wearing-off phenomenon"],"prefix":"10.1016","volume":"103","author":[{"given":"Meral","family":"Sefero\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-5285","authenticated-orcid":false,"given":"Abdulkadir","family":"Tun\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali \u00d6zhan","family":"S\u0131vac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynel","family":"Karaka\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samet","family":"\u00d6ncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2025.106689_bib0001","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2025.106689_bib0002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585231208311","article-title":"Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity","volume":"30","author":"Bou Rjeily","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106689_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102020","article-title":"End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?","volume":"41","author":"Cath\u00e9rine","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106689_bib0004","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/1352458516645869","article-title":"Information processing speed in multiple sclerosis: past, present, and future","volume":"23","author":"Costa","year":"2017","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106689_bib0005","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1212\/NXI.0000000000000706","article-title":"Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker","volume":"7","author":"Foley","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2025.106689_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II Clinical investigators. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106689_bib0007","article-title":"No increase in symptoms toward the end of the Ocrelizumab infusion cycle in patients with multiple sclerosis: symptom burden on Ocrelizumab: a longitudinal study (SymBOLS)","volume":"13","author":"Kister","year":"2023","journal-title":"Neurol. Clin. Pr."},{"issue":"11","key":"10.1016\/j.msard.2025.106689_bib0008","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2025.106689_bib0009","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/0269215512470269","article-title":"Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis","volume":"27","author":"Larson","year":"2013","journal-title":"Clin. Rehabil."},{"issue":"2","key":"10.1016\/j.msard.2025.106689_bib0010","article-title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis","volume":"10","author":"Marian","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"3","key":"10.1016\/j.msard.2025.106689_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2025.106689_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pri.30","article-title":"Reliability of physical functioning measures in ambulatory subjects with MS","volume":"10","author":"Paltamaa","year":"2005","journal-title":"Physiother. Res. Int."},{"issue":"2","key":"10.1016\/j.msard.2025.106689_bib0013","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2025.106689_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106689_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J. Neuroinflammation."},{"issue":"5","key":"10.1016\/j.msard.2025.106689_bib0016","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2025.106689_bib0017","first-page":"80","article-title":"Cognitive assessment has never been faster! the clock drawing test as a screening test for Cognitive impairment in MS clinical practice","volume":"2","author":"Sefero\u011flu","year":"2022","journal-title":"J. Mult. Scler. Res."},{"issue":"4","key":"10.1016\/j.msard.2025.106689_bib0018","first-page":"251","article-title":"Evaluation of cognitive dysfunction by the clock drawing test in multiple sclerosis and clinically isolated syndrome patients: correlation with other neuropsychological tests","volume":"27","author":"Tekin","year":"2022","journal-title":"Neurosci. (Riyadh)"},{"issue":"2","key":"10.1016\/j.msard.2025.106689_bib0019","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106689_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103364","article-title":"The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis","volume":"57","author":"Toorop","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"17","key":"10.1016\/j.msard.2025.106689_bib0021","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2025.106689_bib0022","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1016\/j.msard.2026.107191","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000}},{"DOI":"10.1016\/j.msard.2026.107191","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:20:58Z","timestamp":1774999258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S2211034825004316"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106689","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and cognitive outcomes in Ocrelizumab-treated MS patients: Insights into the wearing-off phenomenon","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106689"}}